Benobio Co. Ltd. has discovered new benzothiophene derivatives acting as bromodomain-containing protein 2 (BD1 domain) (Brd2 BD1) inhibitors reported to be useful for the treatment of cancer.

Elgen Therapeutics Inc. has patented new 4-chromanone derivative proteolysis targeting chimera (PROTAC) compounds comprising a von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled with a WD repeat-containing protein 5 (WDR5; BIG3)-targeting moiety through a linker.

Work at Tango Therapeutics Inc. has led to the identification of new ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

A Genentech Inc. patent discloses compounds which could potentially treat cancer.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized new compounds.

Merck Sharp & Dohme LLC has patented new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Arcus Biosciences Inc. has synthesized new E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Amgen Inc. has reported new 5,6- and 6,6-fused bicyclic alcohols and ethers acting as 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors. They are reported to be useful for the treatment of gastrointestinal disorders.

Researchers from Universita degli Studi di Pavia and Universita degli Studi di Torino have prepared and tested new boron-based compounds for the treatment of Alzheimer’s disease by capture-enhanced neutron irradiation (CENI).

Ventus Therapeutics US Inc. patents describe new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors potentially useful for the treatment of autoimmune disease, rheumatic diseases and liver diseases, among others.